Physician profile
Nathanael Kim
NPI 1710440151
$9,981.89
in general payments reported to CMS, 2019-2025
26 companies · $3,602 in 2025
The $3,602 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $2,369 · 2024: $3,839 · 2025: $3,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,811.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,810.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,303.72 | 2022-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $2,087.25 | 2023-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $883.01 | 2023-2025 | Dificid, Pifeltro, Zerbaxa |
| Abbvie INC. | $832.57 | 2023-2025 | |
| Shionogi INC | $263.23 | 2023-2025 | Fetroja |
| Lundbeck LLC | $237.14 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $225.90 | 2024-2025 | Fanapt |
| Lilly USA, LLC | $160.30 | 2024-2025 | Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $151.96 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Pfizer INC. | $102.45 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $99.69 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.76 | 2023-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $91.67 | 2023 | Quviviq |
| Bavarian Nordic A/S | $66.23 | 2025 | |
| Novo Nordisk INC | $57.93 | 2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $54.68 | 2025 | Wellbutrin, Aplenzin |
| Daiichi Sankyo INC. | $50.59 | 2024 | Injectafer |
| Glaxosmithkline, LLC. | $46.16 | 2022-2023 | Shingrix |
| Astrazeneca Pharmaceuticals Lp | $37.29 | 2024 | Airsupra |
| Philips North America LLC | $28.00 | 2024 | (Ck7) Extended Holter |
| Aimmune Therapeutics, INC. | $23.54 | 2025 | Vowst |
| Seqirus USA INC | $19.60 | 2024 | Flucelvax |
| Vb Spine LLC | $18.04 | 2025 | Everest Spinal System |
| Convatec INC. | $17.75 | 2025 | |
| Corium, LLC | $15.54 | 2023 | Azstarys |
| Phadia US INC. | $13.89 | 2025 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathanael Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.